GlassScriptPhysician profile
Fernando Bobis
NPI 1215171087
$6,200.60
in general payments reported to CMS, 2019-2025
33 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $537 · 2021: $979 · 2022: $561 · 2023: $326 · 2024: $1,283 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,192.85 | 2019-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $648.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $439.31 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $434.44 | 2024-2025 | Lokelma, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $243.78 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $243.49 | 2019-2025 | Capvaxive |
| Allergan, INC. | $239.16 | 2019-2020 | |
| Lilly USA, LLC | $227.56 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Amarin Pharma, INC. | $227.04 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.39 | 2019-2021 | |
| Gilead Sciences, INC. | $185.36 | 2019-2021 | |
| Pfizer INC. | $180.56 | 2024-2025 | |
| Intra-Sana Laboratories | $173.77 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Exact Sciences Corporation | $170.26 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $168.97 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $162.89 | 2024-2025 | Zenpep |
| Amgen INC. | $154.37 | 2020-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $136.84 | 2023-2025 | |
| Ardelyx, INC. | $131.23 | 2025 | Ibsrela |
| Shield Therapeutics INC | $92.39 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.11 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $68.64 | 2021-2024 | |
| Horizon Therapeutics Plc | $66.34 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $53.28 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $51.24 | 2021 | |
| Sumitomo Pharma America, INC. | $50.35 | 2025 | Gemtesa |
| Renalytix Ai, INC. | $41.72 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $34.79 | 2024 | Veozah |
| Phadia US INC. | $25.36 | 2021-2023 | Immunocap |
| Ironwood Pharmaceuticals, INC | $25.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $22.28 | 2024 | Austedo Xr |
| Nestle Healthcare Nutrition INC. | $18.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Bobis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.